143 related articles for article (PubMed ID: 10981485)
1. Management of secondary hyperparathyroidism: the gap between diagnosis and treatment. The Renal Osteodystrophy Multicenter Enquiry.
Díaz-Corte C; Cannata-Andía JB
Am J Med Sci; 2000 Aug; 320(2):107-11. PubMed ID: 10981485
[TBL] [Abstract][Full Text] [Related]
2. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy.
Goodman WG; Ramirez JA; Belin TR; Chon Y; Gales B; Segre GV; Salusky IB
Kidney Int; 1994 Oct; 46(4):1160-6. PubMed ID: 7861712
[TBL] [Abstract][Full Text] [Related]
3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the effects of daily and intermittent-dose calcitriol on serum parathyroid hormone and ionized calcium concentrations in normal cats and cats with chronic renal failure.
Hostutler RA; DiBartola SP; Chew DJ; Nagode LA; Schenck PA; Rajala-Schultz PJ; Drost WT
J Vet Intern Med; 2006; 20(6):1307-13. PubMed ID: 17186842
[TBL] [Abstract][Full Text] [Related]
5. Effects of Denosumab and Calcitriol on Severe Secondary Hyperparathyroidism in Dialysis Patients With Low Bone Mass.
Chen CL; Chen NC; Liang HL; Hsu CY; Chou KJ; Fang HC; Lee PT
J Clin Endocrinol Metab; 2015 Jul; 100(7):2784-92. PubMed ID: 25955225
[TBL] [Abstract][Full Text] [Related]
6. Hyperparathyroidism in CAPD patients: therapy with pulse oral calcitriol.
Juergensen PH; Finkelstein FO; Cooper K; Santacroce S; Kliger AS
Adv Perit Dial; 1993; 9():257-9. PubMed ID: 8105938
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome of calcitriol therapy and patient education program on hyperparathyroidism.
Poole R; Bell N; Diab A
J Ren Nutr; 1999 Apr; 9(2):95-8. PubMed ID: 10089266
[TBL] [Abstract][Full Text] [Related]
8. High prevalence of secondary hyperparathyroidism in chronic kidney disease patients on dialysis in Argentina.
Douthat WG; Castellano M; Berenguer L; Guzmán MA; de Arteaga J; Chiurchiu CR; Massari PU; Garay G; Capra R; de La Fuente JL
Nefrologia; 2013; 33(5):657-66. PubMed ID: 24089157
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of intravenous and subcutaneous calcitriol in the treatment of secondary hyperparathyroidism.
Boran M; Cetin S
Nephron; 1998 Sep; 80(1):119-20. PubMed ID: 9730731
[No Abstract] [Full Text] [Related]
10. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial.
Moe S; Wazny LD; Martin JE
Can J Clin Pharmacol; 2008; 15(1):e36-43. PubMed ID: 18192704
[TBL] [Abstract][Full Text] [Related]
11. Prospective comparison of the effects of maxacalcitol and calcitriol in chronic hemodialysis patients with secondary hyperparathyroidism: a multicenter, randomized crossover study.
Mochizuki T; Naganuma S; Tanaka Y; Iwamoto Y; Ishiguro C; Kawashima Y; Maekawa K; Suda A; Akiba T;
Clin Nephrol; 2007 Jan; 67(1):12-9. PubMed ID: 17269594
[TBL] [Abstract][Full Text] [Related]
12. Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients.
Fukagawa M; Kitaoka M; Yi H; Fukuda N; Matsumoto T; Ogata E; Kurokawa K
Nephron; 1994; 68(2):221-8. PubMed ID: 7830860
[TBL] [Abstract][Full Text] [Related]
13. Oral vitamin D3 pulse therapy for overt secondary hyperparathyroidism at pre-dialysis stage.
Watanabe Y; Inaguma D; Fukuzawa Y; Kumon S; Yamazaki C
Nephrol Dial Transplant; 1996 May; 11(5):910-1. PubMed ID: 8671931
[No Abstract] [Full Text] [Related]
14. Pulse oral versus pulse intraperitoneal calcitriol: a comparison of efficacy in the treatment of hyperparathyroidism and renal osteodystrophy in peritoneal dialysis patients.
Gadallah MF; Arora N; Torres C; Ramdeen G; Schaeffer-Pautz A; Moles K
Adv Perit Dial; 2000; 16():303-7. PubMed ID: 11045316
[TBL] [Abstract][Full Text] [Related]
15. [Effect of calcitriol on secondary hyperparathyroidism].
Xu H; Zhang J; Cheng X; Zhou Q
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Sep; 38(9):920-4. PubMed ID: 24071691
[TBL] [Abstract][Full Text] [Related]
16. Serum parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D3 in patients on maintenance haemodialysis.
Rassoul Z; Mousa D; Rehman MA; Abdalla AH; Hawas F; Popovich W; Gaisoum M; al-Sulaiman M; Al-Khader A
Am J Nephrol; 1995; 15(6):507-11. PubMed ID: 8546173
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients.
Kiattisunthorn K; Wutyam K; Indranoi A; Vasuvattakul S
Nephrology (Carlton); 2011 Mar; 16(3):277-84. PubMed ID: 21342321
[TBL] [Abstract][Full Text] [Related]
18. Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism.
Ong LM; Narayanan P; Goh HK; Manocha AB; Ghazali A; Omar M; Mohamad S; Goh BL; Shah S; Seman MR; Vaithilingam I; Ghazalli R; Rahmat K; Shaariah W; Ching CH;
Nephrology (Carlton); 2013 Mar; 18(3):194-200. PubMed ID: 23311404
[TBL] [Abstract][Full Text] [Related]
19. The molecular basis of secondary hyperparathyroidism in chronic renal failure.
Rahamimov R; Silver J
Isr J Med Sci; 1994 Jan; 30(1):26-31. PubMed ID: 8138394
[TBL] [Abstract][Full Text] [Related]
20. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
Slatopolsky E; Weerts C; Thielan J; Horst R; Harter H; Martin KJ
J Clin Invest; 1984 Dec; 74(6):2136-43. PubMed ID: 6549016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
